FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

[EGBOT]

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.

Source: FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia